Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells $246,773.99 in Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) EVP Jennifer Kayden Lee sold 4,189 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $58.91, for a total value of $246,773.99. Following the completion of the transaction, the executive vice president now owns 4,409 shares of the company's stock, valued at $259,734.19. The trade was a 48.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jennifer Kayden Lee also recently made the following trade(s):

• On Wednesday, February 12th, Jennifer Kayden Lee sold 1,815 shares of Rhythm Pharmaceuticals stock. The shares were sold at an average price of $56.39, for a total value of $102,347.85.
• On Tuesday, February 4th, Jennifer Kayden Lee sold 1,447 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $59.43, for a total transaction of $85,995.21.

Rhythm Pharmaceuticals Price Performance

Shares of NASDAQ:RYTM traded down $0.87 during mid-day trading on Friday, hitting $56.69. The company had a trading volume of 327,086 shares, compared to its average volume of 477,675. Rhythm Pharmaceuticals, Inc. has a one year low of $35.17 and a one year high of $68.58. The firm has a fifty day moving average price of $57.06 and a 200 day moving average price of $53.59. The company has a market capitalization of $3.48 billion, a PE ratio of -13.09 and a beta of 2.14.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on RYTM. Jefferies Financial Group began coverage on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They set a "buy" rating and a $80.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $69.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. Oppenheimer initiated coverage on Rhythm Pharmaceuticals in a research note on Friday, December 20th. They issued an "outperform" rating and a $76.00 price target for the company. Guggenheim assumed coverage on Rhythm Pharmaceuticals in a research note on Monday, October 21st. They issued a "buy" rating and a $70.00 price objective on the stock. Finally, The Goldman Sachs Group increased their target price on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a "buy" rating in a research report on Thursday, December 5th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $68.09.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Castleark Management LLC increased its holdings in shares of Rhythm Pharmaceuticals by 1.3% during the third quarter. Castleark Management LLC now owns 19,260 shares of the company's stock valued at $1,009,000 after acquiring an additional 250 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Rhythm Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,211 shares of the company's stock valued at $114,000 after purchasing an additional 391 shares in the last quarter. SRS Capital Advisors Inc. raised its holdings in Rhythm Pharmaceuticals by 740.7% during the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock worth $25,000 after buying an additional 400 shares during the last quarter. Raleigh Capital Management Inc. bought a new position in shares of Rhythm Pharmaceuticals in the fourth quarter valued at $28,000. Finally, SBI Securities Co. Ltd. acquired a new position in shares of Rhythm Pharmaceuticals during the fourth quarter valued at about $37,000.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.